However, the advisory, published online May 28 in Stroke, still emphasizes ... regulatory authorities for the approval of tPA there — now become exclusion criteria for these new recommendations.

The study is also limited because we were not able to adjust for patient level factors such as time to arrival and other tPA exclusion criteria, stroke severity, patient education, and ...

The study is also limited because we were not able to adjust for patient level factors such as time to arrival and other tPA exclusion criteria, stroke severity, patient education, and ...

Tissue plasminogen activator (tPA) is a medication that doctors administer following a stroke caused by a blood clot. It breaks up the blood clot to allow blood flow to return to the brain.

Administration of intravenous tissue plasminogen activator (tPA) 0–90 min after stroke onset approximately ... hemorrhage should not be an absolute exclusion criterion for thrombolysis, since ...

Older Black patients on Medicare in the United States experience disparities in stroke care access and outcomes, compared with White patients.

But now, some doctors are questioning whether TPA is the best bet for patients. When it comes to a stroke, time is brain. TPA, the only clot-busting drug approved to help lessen the damage ...

"The efficacy of intravenous treatment with [recombinant tissue plasminogen activator] rtPA within three to 4.5 hours after stroke in patients with these exclusion criteria is not well established ...